Satellite Symposia Resources from OncologyPRO sponsors
Find here all the resources from Industry Satellite Symposia published by our industry partners.
Debate: In the modern management of HER2-/HR+ MBC, should chemotherapy be the treatment of last resort?
Eisai Satellite Symposium
Introduction
Presenter: Joseph Gligorov (Paris, France)
Against the Motion – Opening Remarks
Presenter: Javier Cortés (Barcelona, Spain)
For the Motion – Opening Remarks
Presenter: Peter Schmid (London, United Kingdom)
For the Motion – Closing Remarks
Presenter: Peter Schmid (London, United Kingdom)
Against the Motion – Closing Remarks
Presenter: Javier Cortés (Barcelona, Spain)
Close (Thank you)
Presenter: Joseph Gligorov (Paris, France)
Novel Therapies for Relapsed or Refractory HER2-Positive Metastatic Breast Cancer
CME Webinar supported by Daiichi Sankyo
Novel Anti-HER2-Directed ADCs
Presenter: Adam M. Brufsky (Pittsburgh, PA, United States of America)
Novel Targeted Therapies for MBC - Tyrosine kinase inhibitors
Presenter: Cristina Saura Manich (Barcelona, Spain)
Novel Anti-HER2 Monoclonal Antibody
Presenter: Thomas Bachelot (Lyon, France)
Case Discussion: Medical Need for Novel HER2-Directed Options After Failure on Standard-of-Care Treatments
Presenter: Thomas Bachelot (Lyon, France)
A New Decade in the Evolving Treatment Landscape for HER2 Positive Metastatic Breast Cancer
Daiichi Sankyo
Welcome & introduction
Presenter: Javier Cortés (Barcelona, Spain)
Current state-of-the-art in treating HER2 positive metastatic breast cancer
Presenter: Sandra M. Swain (Washington, DC, United States of America)
What is the potential ‘Clinical Value’ of emerging therapies in HER2 metastatic breast cancer?
Presenter: Fatima Cardoso (Lisbon, Portugal)
Concluding remarks
Presenter: Javier Cortés (Barcelona, Spain)
The Power of Choice in HR+, HER2- Advanced Breast Cancer: A Case Continuum
Novartis Satellite Symposium
Welcome and introduction
Presenter: Dejan Juric (Boston, United States of America)
Introduction of the case
Presenter: Dejan Juric (Boston, United States of America)
Presentation and selection of a first-line therapy
Presenter: Fatima Cardoso (Lisbon, Portugal)
Panel discussion
Presenters: Dejan Juric (Boston, United States of America), Fatima Cardoso (Lisbon, Portugal), Hans-Christian Kolberg (Bottrop, Germany)
Spotlight presentation: Fulvestrant as combination partner in both first and second line
Presenters: Dejan Juric (Boston, United States of America), Fatima Cardoso (Lisbon, Portugal), Hans-Christian Kolberg (Bottrop, Germany)
Switching to a second-line treatment
Presenter: Hans-Christian Kolberg (Bottrop, Germany)
Panel discussion
Presenters: Dejan Juric (Boston, United States of America), Fatima Cardoso (Lisbon, Portugal), Hans-Christian Kolberg (Bottrop, Germany)
Putting the Case in Context
Presenter: Dejan Juric (Boston, United States of America)
Panel Discussion: COVID-19 and Patient Management
Presenter: Dejan Juric (Boston, United States of America)
The Evolving Treatment Landscape of Early Triple Negative Breast Cancer
MSD Satellite Symposium
Introduction
Presenter: Sherko Kümmel (Essen, Germany)
Neoadjuvant versus adjuvant therapy: What to consider?
Presenter: Marc Thill (Frankfurt, Germany)
Future perspective on early TNBC: Current developments
Presenter: Frederik Marmé (Mannheim, Germany)
Panel discussion
Presenter: Sherko Kümmel (Essen, Germany)
Summary and Conclusion
Presenter: Sherko Kümmel (Essen, Germany)
Optimising breast cancer outcomes: Clinical and real-world experience lead to strength in numbers
Pfizer Satellite Symposium
What can real-world evidence do for metastatic breast cancer?
Presenter: Nadia Harbeck (Munich, Germany)
From p-values to patient-centricity: refining our approach to metastatic breast cancer treatment
Presenter: Nadia Harbeck (Munich, Germany)
From p-values to patient-centricity: refining our approach to metastatic breast cancer treatment
Presenter: Hope S. Rugo (San Francisco, CA, United States of America)
Emerging therapies in breast cancer: will more options lead to improved outcomes?
Presenter: Nadia Harbeck (Munich, Germany)
How to do more to improve HER2- positive early breast cancer patient outcomes?
Pierre Fabre Satellite Symposium
Welcome and introductions
Presenter: Joseph Gligorov (Paris, France)
Sizing the unmet need in the treatment of early HER2-positive breast cancer
Presenter: Michael Untch (Berlin, Germany)
Optimizing the use of neratinib in the extended adjuvant setting
Presenter: Miguel Martin Jimenez (Madrid, Spain)
Patients stories : one more step to cure
Presenter: Michelino De Laurentiis (Naples, Italy)
Conclusive remarks
Presenter: Joseph Gligorov (Paris, France)
Bringing molecular insights to the clinic: recent advances in Breast Cancer treatment
Roche Satellite Symposium
Welcome and Introduction
Presenter: Rebecca Dent (Singapore, Singapore)
FOUNDATION – Key Recent Advances in Understanding Breast Cancer Biology and Their Contribution to the Development of Targeted Treatments
Presenter: Giampaolo Bianchini (Milan, Italy)
CURRENT CLINICAL IMPLICATIONS – Translating Recent Molecular Biology Insights into Today’s Clinical Practice
Presenter: Sherko Kümmel (Essen, Germany)
FUTURE INSIGHTS – How Will Emerging Technologies Shape the Future of Breast Cancer Care?
Presenter: Rebecca Dent (Singapore, Singapore)
Key Insights and Conclusions
Presenter: Rebecca Dent (Singapore, Singapore)
Improving outcomes after T-DM1 A new horizon for HER2+ mBC patients
Seattle Genetics Satellite Symposium
Chair’s Welcome
Presenter: Alicia Okines (London, United Kingdom)
Shifting paradigms in HER2+ mBC with new treatment approaches
Presenter: Cristina Saura Manich (Barcelona, Spain)
New frontiers in the management of HER2+ brain metastases
Presenter: Thomas Bachelot (Lyon, France)
Data discussion and impact on patients
Presenters: Alicia Okines (London, United Kingdom), Thomas Bachelot (Lyon, France), Cristina Saura Manich (Barcelona, Spain)
Conclusions
Presenter: Alicia Okines (London, United Kingdom)